Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SY-5007 |
Synonyms | |
Therapy Description |
SY-5007 is a RET inhibitor with activity against resistance mutations including M918T, G810S, and V804M, which potentially decreases tumor cell proliferation and tumor growth (PMID: 39489747). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SY-5007 | SY5007|SY 5007 | RET Inhibitor 53 | SY-5007 is a RET inhibitor with activity against resistance mutations including M918T, G810S, and V804M, which potentially decreases tumor cell proliferation and tumor growth (PMID: 39489747). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634W | Advanced Solid Tumor | sensitive | SY-5007 | Preclinical - Cell culture | Actionable | In a preclinical study, SY-5007 inhibited proliferation in cells expressing RET C634W in culture (PMID: 39489747). | 39489747 |
RET fusion | lung non-small cell carcinoma | sensitive | SY-5007 | Phase I | Actionable | In a Phase I trial, SY-5007 therapy was tolerable and led to an objective response rate (ORR) of 57.8% (67/116, 67 partial responses), disease control rate (DCR) of 95.7% (111/116), and median progression-free survival of 21.1 mo in advanced solid tumor patients with RET fusions or alterations, and an ORR of 64.1% (41/64) and DCR of 96.9% (62/64) at the phase II dose in non-small cell lung cancer patients with KIF5B (n=51), CCDC6 (n=12), NCOA4 (n=1), or other RET fusions (n=4) (PMID: 39489747; NCT05278364). | 39489747 |
RET M918T | medullary thyroid carcinoma | sensitive | SY-5007 | Phase I | Actionable | In a Phase I trial, SY-5007 treatment demonstrated safety and resulted in an objective response rate (ORR) of 57.8% (67/116, partial responses), a disease control rate (DCR) of 95.7% (111/116), and a median progression-free survival of 21.1 mo in advanced solid tumor patients harboring RET fusions or alterations, with an ORR of 52.2% (12/23) and DCR of 91.3% (21/23) at the phase II dose in medullary thyroid cancer patients harboring RET M918T (n=15) or other mutations (n=8) (PMID: 39489747; NCT05278364). | 39489747 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|